title: 5T4 oncofetal antigen in gastric carcinoma and its clinical significance.
abstract: OBJECTIVE
  To evaluate the role of 5T4 antigen in gastric cancer progression and prognosis.
  
  
  METHODS
  A prospective study of 5T4 antigen expression in primary, secondary and recurrent gastric carcinoma, the relationship to selected prognostic parameters and the course of disease.
  
  
  METHODS
  Eighty six patients operated on for gastric cancer. TISSUE: One hundred and twenty two gastric tumours were studied, including 86 primary carcinomas, 32 coexisting lymph node metastases and four recurrent carcinomas.
  
  
  METHODS
  Immunohistochemistry using 5T4 monoclonal antibody on frozen sections.
  
  
  RESULTS
  The 5T4 antigen was detected in 41% of primary gastric tumours including early gastric cancer. A strong relationship was found between 5T4 positivity and tumour histology. Thus, 52% of gastric carcinomas of intestinal type expressed 5T4 antigen compared with 28% of the diffuse type (P = 0.028). Among 16 sets of primary gastric carcinomas and regional lymph node metastases, coordinate 5T4 expression was seen in 14 cases; the other two showed acquisition of positivity on metastatic tumour cells (carcinomas of diffuse type). 5T4 antigen was detected more frequently in carcinomas with p53 accumulation compared with those with undetectable p53 levels (P = 0.015). The presence of 5T4 in cancer cells was correlated with poor short-term prognosis (24% vs 49% of 2 year survival for 5T4 positive and negative tumours respectively, P = 0.024). The effect on survival was evident in the p53 negative group, with patients 5T4 positive showing worse survival (28% vs 60% in 2 years).
  
  
  CONCLUSIONS
  Our results suggest that the assessment of 5T4 expression in gastric carcinoma can be helpful in identifying patients with poor short-term prognosis.
authors.affiliation: Department of Gastroenterology, Medical Pomeranian Academy, Szczecin, Poland.
authors.forename: T
authors.initials: T
authors.lastname: Starzynska
authors.forename: A
authors.initials: A
authors.lastname: Wiechowska-Kozlowska
authors.forename: K
authors.initials: K
authors.lastname: Marlicz
authors.forename: M
authors.initials: M
authors.lastname: Bromley
authors.forename: S A
authors.initials: SA
authors.lastname: Roberts
authors.forename: M
authors.initials: M
authors.lastname: Lawniczak
authors.forename: B
authors.initials: B
authors.lastname: Kolodziej
authors.forename: A
authors.initials: A
authors.lastname: Zyluk
authors.forename: P L
authors.initials: PL
authors.lastname: Stern
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000951:Antigens, Neoplasm / Q000378:metabolism*; D014408:Biomarkers, Tumor / Q000378:metabolism*; D018450:Disease Progression; D005260:Female; D006801:Humans; D007124:Immunoenzyme Techniques; D008207:Lymphatic Metastasis; D008297:Male; D008562:Membrane Glycoproteins / Q000378:metabolism*; D008875:Middle Aged; D009364:Neoplasm Recurrence, Local / Q000276:immunology / Q000378:metabolism; D009367:Neoplasm Staging; D011237:Predictive Value of Tests; D011379:Prognosis; D011446:Prospective Studies; D013274:Stomach Neoplasms / Q000276:immunology* / Q000378:metabolism / Q000401:mortality / Q000473:pathology; D016019:Survival Analysis
chemical_list: D000951:Antigens, Neoplasm; D014408:Biomarkers, Tumor; D008562:Membrane Glycoproteins; C063709:trophoblastic glycoprotein 5T4, human